Shanghai Henlius Biotech (HKG:2696) dosed the first patient in a phase 2 clinical study of HLX43 for injection in Spain, according to a Thursday filing with the Hong Kong bourse.
The study aims to evaluate the drug in patients with advanced non-small cell lung cancer.
The phase 2 trial is also ongoing in Mainland China, the U.S., Australia, and Japan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments